Back Human Papillomavirus (HPV) Anal & Cervical Cancer

Anal & Cervical Cancer

Cervarix Vaccine Protects Women against HPV that Causes Anal Cancer

The Cervarix human papillomavirus (HPV) vaccine reduced anal infection with cancer-causing HPV types 16 and 18 in a study of women in Costa Rica, according to a report in the September 2011 issue of The Lancet Oncology.alt

Read more:

HPV Vaccine Reduces Cervical Abnormalities

Vaccination of young women in Australia against human papillomavirus (HPV) lowered incidence of serious cervical cell abnormalities and early cervical cancer by nearly 40%. alt

Read more:

Anal Pap Screening of HIV+ Men Reveals Half Have Abnormal Cells

More than 80% of HIV positive men agreed to undergo Pap screening for anal cancer, demonstrating its feasibility, and 53% showed signs of potentially pre-cancerous abnormal cell growth.

Read more:

Lopinavir Fights HPV in Cervical Cancer Cells

The HIV protease inhibitor lopinavir (the main drug in Kaletra) blocked viral proteasome activitation and selectively killed pre-cancerous cervical cells infected with human papillomavirus (HPV).

As reported in the May 3, 2011, advance online edition of Antiviral Therapy, Gavin Batman and Ian Hampson from the University of Manchester in the U.K. and colleagues tested lopinavir in HPV-infected SiHa cervical carcinoma cells in a laboratory study.

Read more:

Gardasil HPV Vaccine Approved for Anal Cancer

On December 22, 2010, the U.S. Food and Drug Administration (FDA) approved the use of Merck's quadrivalent human papillomavirus (HPV) vaccine, Gardasil, for prevention of anal cancer in men and women age 9-26 years. The vaccine -- which targets high-risk HPV types 6, 11, 16, and 18 -- was previously approved for prevention of cervical cancer in young women.

Read more: